within Pharmacolibrary.Drugs.ATC.R;

model R03AK07
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0016666666666666668,
    adminDuration  = 600,
    adminMass      = 12 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.2,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.16,
    k12             = 70,
    k21             = 70
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>R03AK07</td></tr><td>route:</td><td>inhalation</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Formoterol and budesonide is a fixed-dose combination inhaler containing formoterol, a long-acting beta2-adrenoceptor agonist, and budesonide, an inhaled corticosteroid. This combination is widely used for the regular treatment and prevention of asthma and chronic obstructive pulmonary disease (COPD). It is approved and commonly prescribed worldwide.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult subjects after inhaled administration of formoterol/budesonide combination.</p><h4>References</h4><ol><li><p> (2020). Drugs for COPD. <i>The Medical letter on drugs and therapeutics</i> 62(1606) 137–144. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32960872/&quot;>https://pubmed.ncbi.nlm.nih.gov/32960872</a></p></li><li><p>Dorinsky, P, et al., &amp; Reisner, C (2018). Safety and pharmacokinetics of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler (BGF MDI) in healthy adult subjects of Japanese descent. <i>Pulmonary pharmacology &amp; therapeutics</i> 51 18–25. DOI:<a href=&quot;https://doi.org/10.1016/j.pupt.2018.05.001&quot;>10.1016/j.pupt.2018.05.001</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29763659/&quot;>https://pubmed.ncbi.nlm.nih.gov/29763659</a></p></li><li><p>McGavin, JK, et al., &amp; Jarvis, B (2001). Inhaled budesonide/formoterol combination. <i>Drugs</i> 61(1) 71–80. DOI:<a href=&quot;https://doi.org/10.2165/00003495-200161010-00007&quot;>10.2165/00003495-200161010-00007</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11217872/&quot;>https://pubmed.ncbi.nlm.nih.gov/11217872</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end R03AK07;
